dehydroepiandrosterone has been researched along with Adverse Drug Event in 2 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The majority of the drugs which inhibited steroid ST activities strongly were either synthetic steroids, antisteroidals or were tertiary amine drugs such as tricyclic antidepressants and antihistamines, many of which exhibit adverse side effects manifesting particularly as sexual dysfunction and disruption of hormone action in clinical use." | 1.28 | Inhibition of human liver steroid sulfotransferase activities by drugs: a novel mechanism of drug toxicity? ( Bamforth, KJ; Coughtrie, MW; Dalgliesh, K, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pietri, E | 1 |
| Massa, I | 1 |
| Bravaccini, S | 1 |
| Ravaioli, S | 1 |
| Tumedei, MM | 1 |
| Petracci, E | 1 |
| Donati, C | 1 |
| Schirone, A | 1 |
| Piacentini, F | 1 |
| Gianni, L | 1 |
| Nicolini, M | 1 |
| Campadelli, E | 1 |
| Gennari, A | 1 |
| Saba, A | 1 |
| Campi, B | 1 |
| Valmorri, L | 1 |
| Andreis, D | 1 |
| Fabbri, F | 1 |
| Amadori, D | 1 |
| Rocca, A | 1 |
| Bamforth, KJ | 1 |
| Dalgliesh, K | 1 |
| Coughtrie, MW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Non Randomized Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)[NCT02000375] | Phase 2 | 20 participants (Actual) | Interventional | 2013-03-31 | Terminated (stopped due to Due to slow recruitment and recent new published data) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for dehydroepiandrosterone and Adverse Drug Event
| Article | Year |
|---|---|
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aroma | 2019 |
1 other study available for dehydroepiandrosterone and Adverse Drug Event
| Article | Year |
|---|---|
Inhibition of human liver steroid sulfotransferase activities by drugs: a novel mechanism of drug toxicity?
Topics: Cytosol; Dehydroepiandrosterone; Drug-Related Side Effects and Adverse Reactions; Humans; In Vitro T | 1992 |